Travere Therapeutics, Inc. Common Stock TVTX
Analyst Ratings
- Consensus
- Buy — 9 Buy · 1 Hold · 0 Sell (10 analysts)
- Avg. Price Target
- $67.30 (+28.3% upside)
Key Stats
- Today's Range
- $49.16 – $52.80
- 50-Day Range
- $44.73 – $68.73
- 52-Week Range
- $22.59 – $68.73
- Volume
- 1.15 million shs
- Average Volume
- 2.21 million shs
- Market Cap
- $4.66 billion
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 4.98%
- Days to Cover
- 14.60
About Travere Therapeutics, Inc. Common Stock
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.
Related Stocks
Compare head-to-head: TVTX vs LLY·TVTX vs JNJ·TVTX vs ABBV·TVTX vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.